Immune Checkpoint Inhibitor-Related Pneumonitis

被引：41
|
作者：
Gomatou, Georgia [1 ,2 ]
Tzilas, Vasilios [1 ]
Kotteas, Elias [2 ]
Syrigos, Konstantinos [2 ]
Bouros, Demosthenes [1 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Sotiria Hosp Dis Chest, Dept Resp Med 1, Interstitial Lung Dis Unit, Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Sotiria Hosp Dis Chest, Dept Med 3, Oncol Unit, Athens, Greece
来源：
RESPIRATION | 2021年 / 99卷 / 11期
关键词：
Immune checkpoint inhibitor; Immunotherapy; Pneumonitis; Interstitial lung disease; CELL LUNG-CANCER; ADVERSE EVENTS; COMBINATION IMMUNOTHERAPY; NIVOLUMAB; TOXICITY; RISK; PEMBROLIZUMAB; ASSOCIATION; DOCETAXEL; DIAGNOSIS;
D O I：
10.1159/000509941
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Immune checkpoint inhibitors are novel agents that have been proved efficacious in a variety of cancer types, but they are associated with a unique set of organ-specific, immune-related adverse events. Among them, immune-related pneumonitis requires special attention because it is difficult to diagnose and potentially lethal. Accumulating real-world epidemiological data suggest that immune-related pneumonitis is more frequent than previously reported. Its diagnosis requires exclusion of other causes and assessment of radiographic features on high-resolution CT of the chest. Management of immune-related pneumonitis is based on the use of immunosuppressants. Future research should be focused on finding predictive biomarkers for immune-related pneumonitis as well as optimizing its management.
引用
收藏
页码：932 / 942
页数：11
相关论文
共 50 条
  • [41] Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer
    Tao, Haitao
    Li, Fangfang
    Wu, Dongxiao
    Ji, Shiyu
    Liu, Qingyan
    Wang, Lijie
    Liu, Bo
    Facchinetti, Francesco
    Leong, Tracy L.
    Passiglia, Francesco
    Hu, Yi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (03) : 381 - +
  • [42] Multidisciplinary Approach of Immune Checkpoint Inhibitor-Related Pneumonitis: A Key to Address Knowledge and Management Gaps
    Perol, Maurice
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (08) : 1261 - 1264
  • [43] Association of Clinical and Radiological Features with Disease Severity of Symptomatic Immune Checkpoint Inhibitor-Related Pneumonitis
    Zhang, Qian
    Tao, Xiuli
    Zhao, Shijun
    Li, Ning
    Wang, Shuhang
    Wu, Ning
    DIAGNOSTICS, 2023, 13 (04)
  • [44] Rheumatologic immune checkpoint inhibitor-related adverse events
    Defoe, Melissa
    Bermas, Bonnie L.
    CURRENT OPINION IN RHEUMATOLOGY, 2023, 35 (03) : 141 - 148
  • [45] Nivolumab/pembrolizumabImmune checkpoint inhibitor-related pneumonitis: 4 case reports
    Reactions Weekly, 2020, 1832 (1) : 228 - 228
  • [46] Categorizing Steroid-Response Types in Checkpoint Inhibitor-Related Pneumonitis
    Zhou, C.
    Yang, Y.
    Lin, X.
    Li, S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S259 - S259
  • [47] Successful treatment of immune checkpoint inhibitor-related periaortitis
    Buhrer, Elias D.
    Alberts, Ian L.
    Christ, Lisa
    Ozdemir, Berna C.
    SWISS MEDICAL WEEKLY, 2024, 154
  • [48] Immune Checkpoint Inhibitor-Related Myocarditis and Overlapping Syndromes
    Heffernan, Shannon
    Chen, Yimin
    Tehrani, Babak
    Ewer, Steven
    Hillerson, Dustin
    Rahko, Peter S.
    CIRCULATION, 2023, 148
  • [49] Clinical features of immune checkpoint inhibitor-related cardiotoxicity
    Kirichenko, Y. Yulia
    Belenkov, Y.
    Lyon, A. R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 564 - 564
  • [50] Immune checkpoint inhibitor-related risk of pulmonary AEs
    Reactions Weekly, 2024, 1997 (1) : 12 - 12
12345